Dermapharm Holding SE
XETRA:DMP

Watchlist Manager
Dermapharm Holding SE Logo
Dermapharm Holding SE
XETRA:DMP
Watchlist
Price: 37.5 EUR Market Closed
Market Cap: 2B EUR
Have any thoughts about
Dermapharm Holding SE?
Write Note

Intrinsic Value

The intrinsic value of one DMP stock under the Base Case scenario is 44.03 EUR. Compared to the current market price of 37.5 EUR, Dermapharm Holding SE is Undervalued by 15%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

DMP Intrinsic Value
44.03 EUR
Undervaluation 15%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Dermapharm Holding SE

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for DMP cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about DMP?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Dermapharm Holding SE

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Dermapharm Holding SE

Provide an overview of the primary business activities
of Dermapharm Holding SE.

What unique competitive advantages
does Dermapharm Holding SE hold over its rivals?

What risks and challenges
does Dermapharm Holding SE face in the near future?

Has there been any significant insider trading activity
in Dermapharm Holding SE recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Dermapharm Holding SE.

Provide P/S
for Dermapharm Holding SE.

Provide P/E
for Dermapharm Holding SE.

Provide P/OCF
for Dermapharm Holding SE.

Provide P/FCFE
for Dermapharm Holding SE.

Provide P/B
for Dermapharm Holding SE.

Provide EV/S
for Dermapharm Holding SE.

Provide EV/GP
for Dermapharm Holding SE.

Provide EV/EBITDA
for Dermapharm Holding SE.

Provide EV/EBIT
for Dermapharm Holding SE.

Provide EV/OCF
for Dermapharm Holding SE.

Provide EV/FCFF
for Dermapharm Holding SE.

Provide EV/IC
for Dermapharm Holding SE.

Show me price targets
for Dermapharm Holding SE made by professional analysts.

What are the Revenue projections
for Dermapharm Holding SE?

How accurate were the past Revenue estimates
for Dermapharm Holding SE?

What are the Net Income projections
for Dermapharm Holding SE?

How accurate were the past Net Income estimates
for Dermapharm Holding SE?

What are the EPS projections
for Dermapharm Holding SE?

How accurate were the past EPS estimates
for Dermapharm Holding SE?

What are the EBIT projections
for Dermapharm Holding SE?

How accurate were the past EBIT estimates
for Dermapharm Holding SE?

Compare the revenue forecasts
for Dermapharm Holding SE with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Dermapharm Holding SE and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Dermapharm Holding SE against its competitors.

Analyze the profit margins
(gross, operating, and net) of Dermapharm Holding SE compared to its peers.

Compare the P/E ratios
of Dermapharm Holding SE against its peers.

Discuss the investment returns and shareholder value creation
comparing Dermapharm Holding SE with its peers.

Analyze the financial leverage
of Dermapharm Holding SE compared to its main competitors.

Show all profitability ratios
for Dermapharm Holding SE.

Provide ROE
for Dermapharm Holding SE.

Provide ROA
for Dermapharm Holding SE.

Provide ROIC
for Dermapharm Holding SE.

Provide ROCE
for Dermapharm Holding SE.

Provide Gross Margin
for Dermapharm Holding SE.

Provide Operating Margin
for Dermapharm Holding SE.

Provide Net Margin
for Dermapharm Holding SE.

Provide FCF Margin
for Dermapharm Holding SE.

Show all solvency ratios
for Dermapharm Holding SE.

Provide D/E Ratio
for Dermapharm Holding SE.

Provide D/A Ratio
for Dermapharm Holding SE.

Provide Interest Coverage Ratio
for Dermapharm Holding SE.

Provide Altman Z-Score Ratio
for Dermapharm Holding SE.

Provide Quick Ratio
for Dermapharm Holding SE.

Provide Current Ratio
for Dermapharm Holding SE.

Provide Cash Ratio
for Dermapharm Holding SE.

What is the historical Revenue growth
over the last 5 years for Dermapharm Holding SE?

What is the historical Net Income growth
over the last 5 years for Dermapharm Holding SE?

What is the current Free Cash Flow
of Dermapharm Holding SE?

Discuss the annual earnings per share (EPS)
trend over the past five years for Dermapharm Holding SE.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Dermapharm Holding SE

Current Assets 623.1m
Cash & Short-Term Investments 124.4m
Receivables 124.5m
Other Current Assets 374.2m
Non-Current Assets 1.5B
Long-Term Investments 84.2m
PP&E 317.4m
Intangibles 1.1B
Other Non-Current Assets -2k
Current Liabilities 374.9m
Accounts Payable 92.2m
Other Current Liabilities 282.8m
Non-Current Liabilities 1.2B
Long-Term Debt 904.6m
Other Non-Current Liabilities 259.9m
Efficiency

Earnings Waterfall
Dermapharm Holding SE

Revenue
1.2B EUR
Cost of Revenue
-409.6m EUR
Gross Profit
749.3m EUR
Operating Expenses
-543.3m EUR
Operating Income
206.1m EUR
Other Expenses
-115.5m EUR
Net Income
90.6m EUR

Free Cash Flow Analysis
Dermapharm Holding SE

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

DMP Profitability Score
Profitability Due Diligence

Dermapharm Holding SE's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Year Average ROE
Positive Free Cash Flow
Positive Operating Income
60/100
Profitability
Score

Dermapharm Holding SE's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

DMP Solvency Score
Solvency Due Diligence

Dermapharm Holding SE's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Average D/E
Average Altman Z-Score
36/100
Solvency
Score

Dermapharm Holding SE's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

DMP Price Targets Summary
Dermapharm Holding SE

Wall Street analysts forecast DMP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DMP is 48.58 EUR with a low forecast of 41.92 EUR and a high forecast of 52.5 EUR.

Lowest
Price Target
41.92 EUR
12% Upside
Average
Price Target
48.58 EUR
30% Upside
Highest
Price Target
52.5 EUR
40% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for DMP?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for DMP is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

DMP Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Dermapharm Holding SE Logo
Dermapharm Holding SE

Country

Germany

Industry

Pharmaceuticals

Market Cap

2B EUR

Dividend Yield

4.69%

Description

Dermapharm Holding SE engages in the development, manufacture and market of patent-free pharmaceutical products. The company is headquartered in Gruenwald, Bayern and currently employs 2,373 full-time employees. The company went IPO on 2018-02-09. The firm operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. The company holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The firm offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. The company is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.

Contact

BAYERN
Gruenwald
Lil-Dagover-Ring 7
+4989641860.0
ir.dermapharm.de

IPO

2018-02-09

Employees

2 373

Officers

CEO & Chairman of the Management Board
Dr. Hans-Georg Feldmeier
CFO, Chief Compliance Officer & Member of Management Board
Mr. Christof Dreibholz
Chief Marketing Officer & Member of Management Board
Dr. Andreas Eberhorn
Head of Investor Relations & Corporate Communications
Ms. Britta Hamberger

See Also

Discover More
What is the Intrinsic Value of one DMP stock?

The intrinsic value of one DMP stock under the Base Case scenario is 44.03 EUR.

Is DMP stock undervalued or overvalued?

Compared to the current market price of 37.5 EUR, Dermapharm Holding SE is Undervalued by 15%.

Back to Top